GCM
NRIX icon

Graham Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Graham Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,210
Closed -$150K – 1476
2025
Q3 		$150K Buy
+16,210
New +$168K ﹤0.01% 1119
2023
Q3 		– Sell
-10,783
Closed -$108K – 1205
2023
Q2 		$108K Buy
+10,783
New +$110K ﹤0.01% 883
2022
Q2 		– Sell
-12,350
Closed -$173K – 1169
2022
Q1 		$173K Buy
+12,350
New +$219K 0.01% 838

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's NRIX Position: Q4 2025 in Review

Graham Capital Management sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 16,210 shares — an estimated $150K sold.

Graham Capital Management first reported a position in NRIX in Q1 2022 and held it in 3 quarters. The position peaked at $173K in Q1 2022. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Graham Capital Management reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 16,210 Nurix Therapeutics shares in Q4 2025, an estimated $150K.
  • Graham Capital Management first reported a position in Nurix Therapeutics in Q1 2022 and held it in 3 quarters.
  • Graham Capital Management's Nurix Therapeutics position peaked at $173K in Q1 2022.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.